CORRECTION: Hypha Laboratories Reveals New Patent Applications for Novel Artificial Intelligence (A.I.) Driven In-Home Mycelium Production
Hypha Labs (OTC PINK:DIGP) has expanded its patent portfolio with new filings at the USPTO for novel methods and devices in mycelium processing. The company aims to develop the first in-home device for producing functional mushroom ingredients in less than ten days, with greater potency precision and at lower costs than current market options.
Key points:
- The U.S. functional and psychedelic mushroom market reached $3.6 billion in 2022, with expected 12.1% CAGR from 2023 to 2030.
- Hypha Labs is using AI and machine learning to optimize mycelium processing for extracting active components like psilocybin.
- The new methods aim to overcome traditional challenges in mycelium processing, offering faster cultivation times and more efficient production.
Hypha Labs (OTC PINK:DIGP) ha ampliato il suo portafoglio brevetti con nuove domande presso l'USPTO per metodi e dispositivi innovativi nel trattamento del micelio. L'azienda mira a sviluppare il primo dispositivo domestico per la produzione di ingredienti fungini funzionali in meno di dieci giorni, con maggiore precisione nella potenza e a costi inferiori rispetto alle opzioni attuali sul mercato.
Punti chiave:
- Il mercato statunitense dei funghi funzionali e psicoattivi ha raggiunto 3,6 miliardi di dollari nel 2022, con una CAGR del 12,1% prevista dal 2023 al 2030.
- Hypha Labs sta utilizzando AI e apprendimento automatico per ottimizzare il trattamento del micelio ed estrarre componenti attivi come la psilocibina.
- I nuovi metodi mirano a superare le sfide tradizionali nel trattamento del micelio, offrendo tempi di coltivazione più rapidi e una produzione più efficiente.
Hypha Labs (OTC PINK:DIGP) ha ampliado su cartera de patentes con nuevos registros en la USPTO para métodos y dispositivos novedosos en el procesamiento de micelio. La compañía tiene como objetivo desarrollar el primer dispositivo doméstico para producir ingredientes de hongos funcionales en menos de diez días, con una mayor precisión de potencia y a costos más bajos que las opciones actuales del mercado.
Puntos clave:
- El mercado estadounidense de hongos funcionales y psicoactivos alcanzó 3.6 mil millones de dólares en 2022, con una CAGR del 12.1% proyectada desde 2023 hasta 2030.
- Hypha Labs está utilizando IA y aprendizaje automático para optimizar el procesamiento de micelio y extraer componentes activos como la psilocibina.
- Los nuevos métodos buscan superar los desafíos tradicionales en el procesamiento de micelio, ofreciendo tiempos de cultivo más rápidos y una producción más eficiente.
하이파랩스 (OTC PINK:DIGP)는 균사체 처리에 대한 새로운 방법과 장치에 대해 USPTO에 새로운 특허 출원을 하여 특허 포트폴리오를 확장했습니다. 이 회사는 기능성 버섯 성분을 10일 이내에 생산할 수 있는 최초의 가정용 장치를 개발하는 것을 목표로 하며, 현재 시장 옵션보다 더 높은 효능 정밀도와 더 낮은 비용으로 제품을 제공합니다.
주요 사항:
- 미국의 기능성 및 환각성 버섯 시장은 2022년 36억 달러에 도달했으며, 2023년부터 2030년까지 12.1% CAGR가 예상됩니다.
- 하이파랩스는 AI와 머신러닝을 활용하여 활성 성분인 실로시빈을 추출하는 균사체 처리를 최적화하고 있습니다.
- 새로운 방법은 균사체 처리의 전통적인 문제를 극복하고 더 빠른 재배 시간과 더 효율적인 생산을 제공합니다.
Hypha Labs (OTC PINK:DIGP) a élargi son portefeuille de brevets avec de nouvelles demandes auprès de l'USPTO pour des méthodes et dispositifs innovants dans le traitement du mycélium. L'entreprise vise à développer le premier dispositif domestique pour produire des ingrédients de champignon fonctionnel en moins de dix jours, avec une plus grande précision de puissance et à des coûts inférieurs par rapport aux options disponibles sur le marché.
Points clés :
- Le marché américain des champignons fonctionnels et psychédéliques a atteint 3,6 milliards de dollars en 2022, avec un TCAC de 12,1% prévu de 2023 à 2030.
- Hypha Labs utilise l'IA et l'apprentissage automatique pour optimiser le traitement du mycélium afin d'extraire des composants actifs comme la psilocybine.
- Les nouvelles méthodes visent à surmonter les défis traditionnels du traitement du mycélium, offrant des temps de culture plus rapides et une production plus efficiente.
Hypha Labs (OTC PINK:DIGP) hat sein Patentportfolio mit neuen Anmeldungen beim USPTO für neuartige Methoden und Geräte zur Verarbeitung von Mycel erweitert. Das Unternehmen strebt an, das erste Heimgerät zur Herstellung von funktionalen Pilzzutaten in weniger als zehn Tagen zu entwickeln, mit größerer Wirkstoffgenauigkeit und niedrigeren Kosten als die aktuellen Marktoptionen.
Wichtige Punkte:
- Der US-Markt für funktionale und psychedelische Pilze erreichte im Jahr 2022 3,6 Milliarden Dollar und erwartet eine CAGR von 12,1% von 2023 bis 2030.
- Hypha Labs setzt KI und maschinelles Lernen ein, um die Mycelverarbeitung zur Extraktion aktiver Komponenten wie Psilocybin zu optimieren.
- Die neuen Methoden zielen darauf ab, traditionelle Herausforderungen bei der Mycelverarbeitung zu überwinden und schnellere Kultivierungszeiten sowie eine effizientere Produktion zu bieten.
- None.
- None.
This release contains corrected contact information.
Company Intends to Bring First Functional Mushroom Producer to Retail
LAS VEGAS, NV / ACCESSWIRE / July 19, 2024 / Hypha Labs, Inc. (OTC PINK:DIGP), a pioneer in functional mushroom sciences, is pleased to announce the addition of significant mycological innovations to its current patent portfolio. The expanded patent portfolio now includes several filings with the United States Patent and Trademark Office (USPTO) that seek to protect a series of novel methods and devices designed to revolutionize the extraction of active components from mycelium. These active components include psychedelic, functional and medicinal ingredients such as psilocybin.
Hypha Laboratories is intent on bringing the first fully functional in-home device that will allow a consumer to produce their own mushroom-based ingredients in a grow cycle of less than ten days and with greater potency precision than commonly sold mushrooms and mushroom ingredients. These home grown functional mushroom ingredients would be produced at a fraction of current market prices and in the privacy of a residence using the Company's patent pending elegant bioreactor instead of less desirable substrates such as animal waste.
In 2022, the U.S. market for functional and psychedelic mushrooms reached a valuation of USD
The pending patents seek to protect the use of sophisticated machine learning algorithms to process mycelium, the vegetative part of fungi composed of an intricate network of hyphae. The Company believes that this has tremendous potential across various sectors including pharmaceuticals, nutraceuticals, and biotechnology. Traditionally, mycelium processing to produce psilocybin has faced challenges due to prolonged cultivation times and the necessity of soil-based mushroom growth over extended durations. To address these issues, Hypha Labs has introduced groundbreaking Artificial Intelligence (AI) with novel machine learning methods that overcome these barriers, providing a more efficient and sustainable way to process mycelium for cultivating, producing and extracting active psilocybin. The integration of advanced machine learning offers significant advantages, including optimized growth conditions, accelerated processing times, enhanced yield predictability, and reduced resource consumption, thus revolutionizing the mycelium industry.
About Hypha Labs, Inc.
The company has developed revolutionary cutting-edge technology focused on new methods of producing the active ingredients found in functional mushrooms such as psilocybin using its patent-pending bioreactor design. The Company has positioned itself to play an important role in the burgeoning Functional Mushroom industry in addition to being a disruptive force in the psilocybin space which is quickly manifesting into a similar pattern that was seen in the Cannabis Industry both from a medical and recreational usage with several states and cities have now decriminalized it use. Visit us at HyphaLabs.com.
SAFE HARBOR FORWARD LOOKING STATEMENTS:
This press release may contain forward looking statements that are based on current expectations, forecasts, and assumptions that involve risks as well as uncertainties that could cause actual outcomes and results to differ materially from those anticipated or expected, including statements related to the amount and timing of expected revenues related to our financial performance, expected revenue, contracts, and future growth for upcoming quarterly and annual periods. These risks and uncertainties are further defined in filings and reports by the Company with the U.S. Securities and Exchange Commission (SEC) and on the OTC Disclosure & News Service (OTCDNS). Actual results and the timing of certain events could differ materially from those projected in or contemplated by the forward-looking statements due to a number of factors detailed from time to time in our filings with the SEC and/or OTCDNS. Among other matters, the Company may not be able to sustain growth or achieve profitability based upon many factors including but not limited to the risk that we will not be able to find and secure construction contracts and the necessary assets that will enable us to become profitable. Reference is hereby made to cautionary statements set forth in the Company's most recent SEC and/or OTCDNS filings. We have incurred and will continue to incur significant expenses in our development stage, noting that there is no assurance that we will generate enough revenues to offset those costs in both the near and long term. New lines of business in the construction industry may expose us to additional legal and regulatory costs and unknown exposure(s), the impact of which cannot be predicted at this time. Words such as "estimate," "project," "predict," "will," "would," "should," "could," "may," "might," "anticipate," "plan," "intend," "believe," "expect," "aim," "goal," "target," "objective," "likely" or similar expressions that convey the prospective nature of events or outcomes generally indicate forward-looking statements. You should not place undue reliance on these forward-looking statements, which speak only as of this press release. Unless legally required, we undertake no obligation to update, modify or withdraw any forward-looking statements, because of new information, future events or otherwise.
From time to time, the Company may post new and material information on its website or through its social media profiles at the links below:
LN: https://www.linkedin.com/company/hypha-labs-inc/
FB: https://www.facebook.com/hyphalabs
IG: https://www.instagram.com/hyphalabsinc/
Twitter: https://x.com/Hypha_Labs
For more information about Hypha Labs visit HyphaLabs.com
Investor and Media Relations:
Integrity Media Inc.
(888) 216-3595
team@integritymedia.com
SOURCE: Hypha Laboratories
View the original press release on accesswire.com
FAQ
What new patent applications has Hypha Labs (DIGP) filed?
What is the main product Hypha Labs (DIGP) is developing?
How large is the U.S. functional and psychedelic mushroom market in 2022?
How is Hypha Labs (DIGP) using AI in mycelium processing?
What advantages does Hypha Labs' (DIGP) new technology offer over traditional mycelium processing methods?
